Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Analysis of Baseline Factors
Objective: Determine if baseline factors are associated with the apomorphine sublingual film (APL) dose required to achieve FULL “ON.” Background: APL is approved for the…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease
Objective: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy of apomorphine sublingual film (APL) vs levodopa inhalation powder (CVT-301) for “OFF” episodes in Parkinson’s…Apomorphine infusion before subthalamic deep brain stimulation. A prospective comparative study in the same 20 patients.
Objective: The objetive of this study was to compare the benefit of APO and STN-DBS in aPD in terms of motor (off daily hours, UPDRS…Deterioration in oral health status potentially associated with apomorphine pump initiation: a case report
Objective: To describe the case of a patient with Parkinson’s disease (PD) who suffered from a rapid deterioration of his oral health status following treatment…Impact of device-aided therapies on QoL and Off-time improvement in advanced Parkinson’s Disease patients: Comparative effectiveness results from a Bayesian Network Meta-Analysis
Objective: To compare off-time and QoL changes among APD patients taking LCIG, DBS, CSAI, and BMT at 6 months after therapy initiation. Background: Advanced Parkinson’s…Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France
Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…Apomorphine improves pulmonary function in parkinsonian patients
Objective: Aim of the study; to investigate if apomorphine might facilitate weaning from mechanical ventilation in parkinsonian patients. Background: Apomorphine is an effective treatment for PD…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 14
- Next Page »